Lexaria Bioscience Extends Material Transfer Agreement with Pharmaceutical Company

Lexaria Bioscience Corp.'s Material Transfer Agreement with a pharmaceutical company has been extended through April 30, 2026, to accommodate time needed for the company to review the full dataset from Lexaria's Australian study. This will allow the two parties to continue their relationship and contemplate additional strategic planning discussions. Lexaria's DehydraTECH technology has shown potential in pre-clinical studies and the company expects to release the final results of the Australian study before the end of Q4 2025.